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Use of radiotherapy (RT) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) varies according to country,
precedent and prejudice. Results from a preliminary analysis of the data available within the UK Sloane Project can be appreciated in
the context of the uncertainty concerning the selection of adjuvant RT following BCS for DCIS. There was a marked geographical
variation in the use of RT within the United Kingdom. However, overall, patients with DCIS treated with BCS were significantly more
likely to have RT planned (and given) if they had large (X15mm), intermediate or high-grade tumours or if central comedo-type
necrosis was present. Unexpectedly, margin width did not appear to have a significant effect on the decision-making process.
However, the Van Nuys Prognostic Index did significantly affect the chances of getting planned RT in the univariate analysis, suggesting
that clinicians may be starting to use this scoring system in routine practice to assist in decision making.
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The Sloane Project was set up to assess the incidence, patterns of
care and outcome of screen-detected ductal carcinoma in situ
(DCIS) within the UK by prospective collection of radiological,
pathological, surgical, systemic therapy and radiotherapy (RT)
data using specifically designed proforma. All 94 UK NHS breast-
screening units are encouraged to participate. Data collection
began in April 2003 and continues to date. We report the findings
from the start of data collection until June 2006.
There is an increasing use of breast-conserving surgery (BCS) in
preference to mastectomy as definitive surgical therapy for DCIS.
Over the last decade, a number of randomised controlled trials
have confirmed that post-operative whole-breast irradiation (RT)
following BCS for DCIS reduces the risk of both in situ and
invasive recurrence. However, examination of data from clinical
trials to date does not readily allow the identification of patients
who benefit most from, or conversely do not require, RT. A
number of factors, which predict the risk of local recurrence, have
been used either alone or in combination to select patients to
receive RT. We have investigated the use of RT following BCS for
screen-detected DCIS within the Sloane Project database.
MATERIALS AND METHODS
The study group consisted of 1140 patients who underwent BCS for
DCIS (either alone or in combination with lobular in situ neoplasia
and/or atypical ductal hyperplasia) between April 2003 and June
2006 and for whom both treatment and pathology data were
available (Figure 1). Data were available from 69 of the breast
screening units within the United Kingdom. Margin data were
collected on the Sloane Project pathology form. Pathologists were
requested to provide information regarding the width of tumour-
free tissue as far as possible for each individual radial (i.e. not
anterior or deep) margin. For the purposes of the analyses, the
smallest margin width following the final therapeutic excision was
used for any of the radial margins. If the specimen was not
orientated by the surgeon at the time of operation, a single, non-
specified margin measurement was provided. If the only margin
width given was distance to the deep, superficial or nipple margins,
margin status was regarded as ‘unknown’. Radiotherapy treatment
was defined as ‘planned’ if, according to the Sloane Project surgical
treatment form, the intention was to refer a patient for RT, either
with or without endocrine therapy. Radiotherapy treatment was
defined as ‘given’ if a Sloane Project RT treatment form recording
the details of the RT was submitted or other evidence was provided
that the RT treatment had been given.
The planning of RT and actual RT recorded as given were
examined in relation to the pathological characteristics of the DCIS
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sand also with pathological assessment of margin status/width. The
Van Nuys Prognostic Index (VNPI) (Silverstein et al, 1996) was
calculated. The VNPI combines three significant predictors of local
recurrence: tumour size, margin width and pathologic classifica-
tion. Scores of 1 (best) to 3 (worst) are assigned for each of the
three predictors and then totalled to give an overall VNPI score
ranging from three to nine.
Several univariate logistic regression models were fitted to
determine which factors predicted whether RT was planned for, or
actually received by individual patients. The factors were further
examined using a single logistic multivariate regression model
(Armitage and Berry, 1994) to examine the effect of forcing each of
the factors into the model, after adjustment for the other factors. Both
unadjusted and adjusted odds ratios are presented for each level of
the different factors compared with the reference baseline category.
RESULTS
Of the 1613 patients registered within the Sloane Project database,
473 (29.3%) were treated by mastectomy and 1140 (70.7%) by BCS
(Figure 1). Overall, in slightly more than half (651 (57.1%)) of the
1140 patients treated by BCS, the intention to give post-operative
adjuvant RT was recorded on the surgical treatment form. Five
hundred and eighty-five (89.9%) of these 651 cases had a
completed RT form returned. Margin width was available for
87.7% of cases, tumour size for 95.4%, the presence or absence of
comedo necrosis for 97.5% and nuclear grade for 99.0%. A VNPI
could be calculated for 83.2% of patients. Table 1 shows how the
intended (planned) and actual (planned and recorded as given) use
of adjuvant RT varied with excision margin width, pathological
assessment/estimation of the size of the DCIS, the presence of
comedo necrosis, DCIS nuclear grade and VNPI.
Table 1 shows that planned use of adjuvant RT was significantly
higher for larger tumours (82.9% of patients with DCIS 440mm
in diameter compared with only 45.3% of patients with o15mm
diameter tumours), for tumours with a high nuclear grade (73.1%
compared with 17.7% for low-grade DCIS) and for DCIS with
central comedo-type necrosis present (69.9% compared with
33.4%). Logistic regression modelling showed that all of these
factors were highly significant in both the univariate and multi-
variate models predicting the planned use of adjuvant RT. This
indicates that all three factors are strong independent determi-
nants in the decision-making process, after taking the other factors
into account (Table 2).
Planned use of adjuvant RT increased with decreasing excision
margin width for tumours where the excision margins were greater
than 1mm; ranging from 55.2% for tumours with margins
X10mm and 64.6% for tumours with a margin width of 1–
4.99mm (Table 1). However, logistic regression analysis showed
that margin width did not significantly affect whether or not
adjuvant RT was planned (P¼0.09; Table 2). For 49 tumours with
excision margins o1mm (41.9% of those with margins o1mm
and 4.3% of all cases) no adjuvant RT was recorded as being
planned (Table 1). For a further five cases, adjuvant RT was
planned but not given, and for six other cases adjuvant RT was
planned but it was not known whether or not the treatment had
actually been given.
The planned use of adjuvant RT also showed a strong
relationship with VNPI, increasing from 27.1% for tumours with
a score of 3 or 4, to 68.2% for tumours with a score of 5, 6 or 7 and
79.5% for tumours with a score of 8 or 9 (Table 1). This
relationship was observed in a univariate logistic regression model,
with patients with a VNPI of 5–7 being 6 times more likely, and
patients with a VNPI of 8 or 9 being 10 times more likely to have
RT planned compared with patients of VNPI 3 or 4 (Po0.001).
Approx. 9425 patients 
diagnosed with screen-detected 
DCIS in the UK from 1 April 2003 
to 31 March 2006 
1613 (17.1%) 
Sloane Project patients with 
treatment and pathology data
473 (29.3%) cases 
Mastectomy 
1140 (70.7%)
 (BCS)  
7 (1.5%)
RT planned 
438 (92.6%) 
No RT planned
477 (41.8%) 
No RT planned 
651 (57.1%) 
RT planned 
585 (89.9%) 
RT given 
27 (4.1%) 
Unknown if 
RT given 
28 (5.9%)
RT unknown 
12 (1.1%) 
RT unknown
39 (6%) 
RT not given 
Figure 1 Details of the final surgical treatment received by and adjuvant radiotherapy treatment planned and confirmed as given to patients included in
the Sloane Project.
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sTable 1 Variation with pathological factors in the planned and actual use of adjuvant RT for DCIS patients treated with breast-conserving surgery (BCS)
Radiotherapy treatment
RT planned RT planned and given RT planned but not given RT planned but u/k if given RT not planned RT unknown if planned
Pathological factor
Total no.
of cases % cases No. % No. % No. % No. % No. % No. %
Margins
4or¼10mm 417 36.6 230 55.2 206 49.4 17 4.1 7 1.7 180 43.2 7 1.7
5–9.99mm 226 19.8 127 56.2 119 52.7 4 1.8 4 1.8 98 43.4 1 0.4
1–4.99mm 240 21.1 155 64.6 137 57.1 10 4.2 8 3.3 83 34.6 2 0.8
o1mm 117 10.3 68 58.1 63 53.8 3 2.6 2 1.7 49 41.9 0 0.0
Unknown margins 140 12.3 71 50.7 60 42.9 5 3.6 6 4.3 67 47.9 2 1.4
Total 1140 100.0 651 57.1 585 51.3 39 3.4 27 2.4 477 41.8 12 1.1
Tumour size
o15mm 678 59.5 307 45.3 269 39.7 24 3.5 14 2.1 362 53.4 9 1.3
16–40mm 375 32.9 293 78.1 270 72.0 13 3.5 10 2.7 80 21.3 2 0.5
440mm 35 3.1 29 82.9 28 80.0 1 2.9 0 0.0 6 17.1 0 0.0
Unknown size 52 4.6 22 42.3 18 34.6 1 1.9 3 5.8 29 55.8 1 1.9
Total 1140 100.0 651 57.1 585 51.3 39 3.4 27 2.4 477 41.8 12 1.1
Comedo necrosis
Not present 392 34.4 131 33.4 112 28.6 14 3.6 5 1.3 256 65.3 5 1.3
Present 720 63.2 503 69.9 460 63.9 23 3.2 20 2.8 210 29.2 7 1.0
Unknown necrosis 28 2.5 17 60.7 13 46.4 2 7.1 2 7.1 11 39.3 0 0.0
Total 1140 100.0 651 57.1 585 51.3 39 3.4 27 2.4 477 41.8 12 1.1
Nuclear grade
Low 141 12.4 25 17.7 20 14.2 2 1.4 3 2.1 114 80.9 2 1.4
Intermediate 368 32.3 167 45.4 141 38.3 17 4.6 9 2.4 197 53.5 4 1.1
High 620 54.4 453 73.1 419 67.6 19 3.1 15 2.4 161 26.0 6 1.0
Unknown grade 11 1.0 6 54.5 5 45.5 1 9.1 0 0.0 5 45.5 0 0.0
Total 1140 100.0 651 57.1 585 51.3 39 3.4 27 2.4 477 41.8 12 1.1
Van Nuys Score
3,4 236 20.7 64 27.1 52 22.0 9 3.8 3 1.3 168 71.2 4 1.7
5,6,7 673 59.0 459 68.2 423 62.9 20 3.0 16 2.4 209 31.1 5 0.7
8,9 39 3.4 31 79.5 30 76.9 1 2.6 0 0.0 8 20.5 0 0.0
Unknown Van Nuys 192 16.8 97 50.5 80 41.7 9 4.7 8 4.2 92 47.9 3 1.6
Total 1140 100.0 651 57.1 585 51.3 39 3.4 27 2.4 477 41.8 12 1.1
BCS¼breast-conserving surgery; DCIS¼ductal carcinoma in situ;R T¼radiotherapy.
R
a
d
i
o
t
h
e
r
a
p
y
f
o
l
l
o
w
i
n
g
b
r
e
a
s
t
-
c
o
n
s
e
r
v
i
n
g
s
u
r
g
e
r
y
D
D
o
d
w
e
l
l
e
t
a
l
7
2
7
B
r
i
t
i
s
h
J
o
u
r
n
a
l
o
f
C
a
n
c
e
r
(
2
0
0
7
)
9
7
(
6
)
,
7
2
5
–
7
2
9
&
2
0
0
7
C
a
n
c
e
r
R
e
s
e
a
r
c
h
U
K
Clinical StudiesHowever, this effect was no longer statistically significant in the
multivariate model after adjustment for the factors tumour size,
nuclear grade and presence or absence of comedo necrosis
(P¼0.75).
The logistic regression analyses were repeated for the actual use
of adjuvant RT. The findings were very similar to those for the
planned use of adjuvant RT, with tumour size, comedo necrosis
and nuclear grade being the only significant predictors in the
multivariate model (all Po0.001; data not shown).
There was wide variation in the use of adjuvant RT across UK
breast-screening units, with six units not using adjuvant RT at all,
and two units giving adjuvant RT to all of their patients. The
median planned use of adjuvant RT was 57.7% (Figure 2).
DISCUSSION
The number of patients diagnosed with screen-detected DCIS
within the United Kingdom annually is around 2900, and
approximately 70% of these are treated with BCS (NHS Breast
Screening Programme (NHSBSP) and Association of Breast
Surgery (ABS) at BASO, 2007). The study group therefore
comprised around 12% of all incident cases of DCIS diagnosed
during the period April 2003–June 2006 and 17% of those
receiving BCS.
DCIS patients treated with BCS were significantly more likely to
have adjuvant RT planned, and to have been given adjuvant RT, if
their tumours were large (X15mm), if they had either inter-
mediate- or high-grade tumours, or if central comedo-type
necrosis was present. This indicates that knowledge about each
of these factors informs the decision-making process separately.
While there did appear to be a general increase in the planned use
of adjuvant RT with decreasing excision margin width for tumours
where the excision margins were greater than 1mm, this factor was
not significant in the multivariate modelling and so did not
independently predict whether adjuvant RT was planned. The lack
of an overall effect for margin width in the multivariate model is
possibly due to the high percentage of cases who were planned not
to receive RT with margins o1mm, where this may have been
expected to have been given.
The VNPI was seen to affect the chances of getting planned (or
actual) adjuvant RT in the univariate analysis, suggesting that
clinicians may be starting to use this scoring system in routine
practice to assist in decision making. It is possible that the VNPI
not being statistically significantly in the multivariate model, after
adjustment for size and grade, is an artefact of it being included in
the model along with the factors from which it is derived. As such,
it has a higher percentage of cases with unknown VNPI (16.8%)
compared to its components (1.0% for grade, 4.6% for size and
12.3% for margin width). Additionally, the lack of an effect for
Table 2 Unadjusted and adjusted odds ratios of receiving planned RT for DCIS patients having breast-conserving surgery (BCS)
RT planned
Unadjusted Adjusted
Pathological factor Total no. of cases No. % ORs CI P-value ORs CI P-value
Margins 0.07 0.09
4or¼10mm 417 230 55.2 1.0 — 1.0 —
5–9.99mm 226 127 56.2 1.04 0.75, 1.45 1.03 0.70, 1.52
1–4.99mm 240 155 64.6 1.48 1.07, 2.06 1.66 1.12, 2.45
o1mm 117 68 58.1 1.13 0.75, 1.71 1.00 0.58, 1.72
Unknown margins 140 71 50.7 0.84 0.57, 1.23 0.93 0.32, 2.76
Total 1140 651 57.1
Tumour size o0.001 o0.001
o15mm 678 307 45.3 1.0 — 1.0 —
16–40mm 375 293 78.1 4.32 3.24, 5.76 3.50 2.50, 4.90
440mm 35 29 82.9 5.84 2.39, 14.25 5.71 2.16, 15.13
Unknown size 52 22 42.3 0.89 0.50, 1.57 1.06 0.40, 2.86
Total 1140 651 57.1
Comedo necrosis o0.001 o0.001
Not present 392 131 33.4 1.0 — 1.0 —
Present 720 503 69.9 4.62 3.55, 6.01 2.05 1.45, 2.89
Unknown necrosis 28 17 60.7 3.08 1.40, 6.76 2.28 0.90, 5.75
Total 1140 651 57.1
Nuclear grade o0.001 o0.001
Low 141 25 17.7 1.0 — 1.0 —
Intermediate 368 167 45.4 3.86 2.39, 6.22 2.55 1.52, 4.26
High 620 453 73.1 12.59 7.89, 20.08 6.56 3.65, 11.80
Unknown grade 11 6 54.5 5.57 1.57, 19.69 3.48 0.67, 18.13
Total 1140 651 57.1
Van Nuys score o0.001 0.75
3,4 236 64 27.1 1.0 — 1.0 —
5,6,7 673 459 68.2 5.76 4.15, 8.02 0.89 0.54, 1.49
8,9 39 31 79.5 10.41 4.55, 23.85 0.52 0.16, 1.70
Unknown Van Nuys 192 97 50.5 2.74 1.83, 4.11 0.88 0.27, 2.86
Total 1140 651 57.1
BCS¼breast-conserving surgery; DCIS¼ductal carcinoma in situ;R T¼radiotherapy.
Radiotherapy following breast-conserving surgery
D Dodwell et al
728
British Journal of Cancer (2007) 97(6), 725–729 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
smargins of width o1mm may have weakened the relationship.
However, given the strong relationship observed in the univariate
model between the VNPI and whether or not a patient was planned
to receive RT, it seems reasonable to assume that when all of the
components are known, and thus a VNPI can be derived, that this
single prognostic indicator score would have been used to
determine the decision about giving RT or not.
T h e r ew a sav e r yw i d ev a r i a t i o ni nt h eu s eo fa d j u v a n tR Tb y
individual breast units, with some referring all patients treated by
BCS for adjuvant RT and some referring none. Although it should be
acknowledged that the available evidence concerning the utility of
adjuvant RT following BCS for DCIS does allow some interpretational
variation and does not permit a definitive policy to be formulated,
such a wide variation in routine practice is of concern.
Data from the prospective randomised controlled trials (Fisher
et al, 1998; Julien et al, 2000; UK Coordinating Committee on
Cancer Research (UKCCCR) DCIS Working Party, 2003) concern-
ing the use of adjuvant RT have been available for some years; for
example, the UK DCIS I trial (UKCCCR DCIS Working Party,
2003) to which many of the breast units participating in the Sloane
Project contributed, was published 3 years ago. These, albeit
relatively few, trials have shown that adjuvant RT halves the risk of
local recurrence.
It is possible that the variation in use of RT reflected differences
in perception of the risk–benefit relationships of this treatment
given that there is no evidence of any impact of adjuvant therapy
for DCIS on breast cancer mortality but – given the pressures on
RT facilities in the UK (Dodwell and Crellin, 2006) – some
clinicians may feel that priority for patients should be given to
those with invasive disease or at least those at highest risk of
recurrence and therefore decisions concerning the use of RT for
DCIS may reflect local RT capacity.
There is a clear need to establish a coherent approach to the
management of DCIS. Evidence from clinical trials and high-
quality epidemiological studies is required to support the approach
of omitting adjuvant RT for low-risk groups and, in particular, to
identify the characteristics of such groups robustly. Uniform
standards of surgical excision and pathological measurement of
distance to surgical margins are required. Similarly there are no
agreed methodologies, scoring systems or cutoffs for the assess-
ment of hormone receptor status in DCIS in the United Kingdom.
Ongoing prospective trials, as well as the Sloane Project, will aid in
the achievement of these goals and, it is to be hoped, will provide a
better understanding of treatment effectiveness for this increas-
ingly commonly detected disease, thus allowing a more consistent
approach to patient management.
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Figure 2 Variation in the planned use of adjuvant radiotherapy with breast-screening unit.
Radiotherapy following breast-conserving surgery
D Dodwell et al
729
British Journal of Cancer (2007) 97(6), 725–729 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s